Foetal and neonatal alloimmune thrombocytopenia – The role of the HLA-DRB3*01:01 allele for HPA-1a-immunisation and foetal/neonatal outcome. (February 2020)

• Record Type: Journal Article
• Authors: Kjeldsen-Kragh, Jens; Ahlen, Maria Therese
• Is Part Of: Transfusion and apheresis science. Volume 59:Number 1(2020)
• Publication Date: 2020-02
• Subjects: Alloimmunization -- Foetus -- Neonate -- Platelet -- Pregnancy -- HPA-1a -- HLA-DRB3*01:01; Blood -- Transfusion -- Periodicals; Hemapheresis -- Periodicals; 615.39
• DOI: 10.1016/j.transci.2019.102707
• Languages: English
• ISSNs: 1473-0502

Abstract

Abstract: Foetal and neonatal alloimmune thrombocytopenia (FNAIT) is the platelet counterpart of haemolytic disease of the foetus and newborn. Among Caucasians, around 80 % of FNAIT cases and some of the most severe cases, are caused by alloantibodies against the human platelet antigen 1a (HPA-1a). For around 3 decades it has been known that almost all HPA-1a-immunised women are HLA-DRB3*01:01 positive. The HLA molecule encoded by the HLA-DRA/DRB3*01:01 genes seems to be of crucial importance for initiating the immune response against HPA-1a. The HLA-DRB3*01:01 carrier status is not only important as a risk factor for immunisation, but does also have a significant impact on foetal/neonatal outcome. The possible role of HLA-DRB3*01:01 typing as tool for risk stratification is discussed.